Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trialApproximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026Company expects existing resources to support BLOOM